Infectious Mononucleosis Patents (Class 436/812)
-
Patent number: 7524681Abstract: The present invention relates to a method for determining the condition of a biological fluid by recording the IR spectrum of a sample of the biological fluid. To this end, the biological fluid can be examined in its native form. The method of the invention is usable, for example, for detecting pathological conditions in organisms.Type: GrantFiled: January 22, 2002Date of Patent: April 28, 2009Inventors: Andreas Wolf, Ralf Masuch, Robert Seidel
-
Patent number: 6284475Abstract: The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.Type: GrantFiled: July 10, 1998Date of Patent: September 4, 2001Assignee: Mount Sinai School of Medicine of the City of New YorkInventor: Jacob H. Rand
-
Patent number: 5672471Abstract: This disclosure concerns an assay for detecting and/or quantifying a mammalian IgA antibody response to EBV-MA with an immobilized EBV-MA gp 350/220 lacking the transmembrane anchor domain.Type: GrantFiled: October 12, 1995Date of Patent: September 30, 1997Assignee: E. I. Du Pont de Nemours and CompanyInventors: Paul John Durda, Elliott Dan Kieff, Gary Richard Pearson, Harvey Rabin, Marcia Delaney Sullivan
-
Patent number: 5374517Abstract: The invention is directed to the diagnosis and treatment of herpes virus related diseases. By noting within the Epstein-Barr virus (EBV) open reading frames (ORFs) transcribed late in the viral cycle for which a translation product may or may not have been established, and synthesizing one or more polypeptides each of which includes at least one segment, each segment comprising at least part of the amino acid sequence identified in that ORF, a specific and reliable diagnostic test for, and treatment of, infectious mononucleosis and related diseases is possible. The preferred amino acid sequences for these segments include NSPKNG (SEQ ID NO: 12), KNGSNQ (SEQ ID NO: 13), SNQLVI (SEQ ID NO: 14), AHARDK (SEQ ID NO: 15), RDKAGA (SEQ ID NO: 16), VMAMIL (SEQ ID NO: 17), SEPRPR (SEQ ID NO: 18), and PSRTPS (SEQ ID NO: 19).Type: GrantFiled: May 22, 1992Date of Patent: December 20, 1994Assignee: Council of the Queensland Institute of Medical ResearchInventors: Tom B. Sculley, Denis J. Moss
-
Patent number: 5122448Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences--Gly--R.sup.1 --Gly--R.sup.2 --Gly-- (i)wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and--Gly--Ala--Gly--Gly--Ala--Gly--. (ii)The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.Type: GrantFiled: January 11, 1990Date of Patent: June 16, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten
-
Patent number: 5116725Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences(i) --Gly--R.sup.1 --Gly--R.sup.2 --Gly--wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and(ii) --Gly--Ala--Gly--Gly--Ala--Gly--.The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.Type: GrantFiled: November 4, 1987Date of Patent: May 26, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten, Richard S. Smith, John E. Geltosky
-
Patent number: 4853326Abstract: Novel and improved methods for diagnosis, prognosis, prophylaxis and therapy of viral infections are described. The novel methods employ a virus, viral antigen or fragment thereof in which "perturbation" of an oligosaccharide moiety renders the virus, viral antigen or fragment thereof more specifically recognizable or reactive with neutralizing antibody. As described, "perturbation" of an oligosaccharide moiety encompasses any modification that (1) alters the chemical or physical structure of a carbohydrate residue that is naturally present; (2) that removes, wholly or in part, a carbohydrate residue; and/or (3) that prevents or alters addition of a carbohydrate residue. A variety of methods for oligosaccharide "perpetuation" are also described.Type: GrantFiled: November 18, 1986Date of Patent: August 1, 1989Assignee: Cytogen CorporatonInventors: Gerard A. Quash, John D. Rodwell, Thomas J. McKearn, Jean P. Ripoll
-
Patent number: 4525459Abstract: Preparations useful in the diagnosis of infectious mononucleosis are disclosed. Horse and sheep erythrocytes are purified and essentially homogenous glycoproteins are extracted. The purified glycoproteins are useful as antigens in testing for the presence of the heterophile antibodies of infectious mononucleosis and in the preparation of reagents for the enumeration of rosetting lymphocytes without having to have available fresh sheep blood.Type: GrantFiled: January 27, 1982Date of Patent: June 25, 1985Assignee: University of MiamiInventor: Mary A. Fletcher
-
Patent number: 4474886Abstract: Early detection of infectious mononucleosis is carried out using a sample of human blood by isolating and identifying the presence of Inmono proteins in the sample from a two-dimensional protein map with the proteins being characterized by having isoelectric banding as measured in urea of about -16 to -17 with respect to certain isoelectric point standards and molecular mass of about 70 to 75 K daltons as measured in the presence of sodium dodecylsulfate containing polyacrylamide gels, the presence of the Inmono proteins being correlated with the existence of infectious mononucleosis.Type: GrantFiled: August 10, 1982Date of Patent: October 2, 1984Assignee: The United States of America as represented by the United States Department of EnergyInventor: Karen E. Willard
-
Patent number: 4460694Abstract: A novel purification scheme is described for obtaining two novel and useful forms of bovine glycoprotein (BGP) from bovine erythrocytes, each of which acts as an antigen in testing for the presence of the heterophile antibodies of human infectious mononucleosis.The first, or partially purified, BGP is obtained from crude BGP and contains about 10% by weight of a complex glycoplipid. It forms a single band upon gel electrophoresis at pH 7.0 under specified conditions.The second, or homogeneous, BGP is obtained by removing essentially all of the complex glycolipid. It forms substantially a single band upon gel electrophoresis at pH 7.0 under specified conditions.Both forms may be used to detect or quantify hemagglutination inhibition of a test sample (and hence to determine the presence or extent to mononucleosis infection) in a glass slide test wherein the partially purified or homogeneous BGP is carried on latex or synthetic resin beads.Type: GrantFiled: March 9, 1982Date of Patent: July 17, 1984Assignee: University of MiamiInventor: Mary A. Fletcher